# Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)

> **NCT01777763** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 230 (actual)

## Conditions studied

- Fungal Infections

## Interventions

- **DRUG:** Posaconazole 200 mg
- **DRUG:** Posaconazole 300 mg

## Key facts

- **NCT ID:** NCT01777763
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01777763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01777763, "Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01777763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*